New method for producing norathyriol and its uses

The use of Bacillus sp. KM7-1 strain for converting mangiferin to noratiiol under controlled conditions addresses inefficiencies in existing methods, providing a cost-effective and eco-friendly production process.

JP7588308B2Active Publication Date: 2024-11-22MARUZEN PHARMA +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020106495
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-06-19
Publication Date
2024-11-22
Estimated Expiration
2040-06-19

AI Technical Summary

Technical Problem

Current methods for producing noratiiol from mangiferin are inefficient, costly, and environmentally unfriendly, requiring special equipment and substrates, and have low yield and high economic costs.

Method used

A novel method using Bacillus sp. KM7-1 strain to convert mangiferin to noratiiol under aerobic or anaerobic conditions, utilizing dormant or active microbial cells, crushed cells, or cell extracts, without the need for special equipment or substrates, at temperatures below 70°C.

Benefits of technology

The method enables efficient, safe, and environmentally friendly production of noratiiol from mangiferin, reducing costs and stabilizing its supply at low prices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588308000003
    Figure 0007588308000003
  • Figure 0007588308000004
    Figure 0007588308000004
  • Figure 0007588308000005
    Figure 0007588308000005
Patent Text Reader

Abstract

To provide a novel method for producing norathyriol, which can produce norathyriol from mangiferin more easily, efficiently, safely, and environmentally friendly than before; a microorganism that can be suitably used in the production method; and an agent for preparing norathyriol, and also provide methods for producing foods, feeds / baits, cosmetics, pharmaceuticals, or quasi-drugs containing norathyriol.SOLUTION: There is provided a method for producing norathyriol using a microorganism belonging to the genus Bacillus and capable of converting mangiferin to norathyriol.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel method for producing norathyriol, a microorganism that can be suitably used in the production method, an agent for preparing norathyriol, and a method for producing foods, feeds, cosmetics, pharmaceuticals, quasi-drugs, etc. that contain norathyriol. [Background technology]

[0002] Mangiferin, represented by the structural formula below, is a C-glycoside that is abundantly contained in plants such as mango, salacia, and hercampuri. Mangiferin is known to have physiological activities such as hypoglycemic, anti-obesity, and anti-stomach pain effects. [ka]

[0003] Norathyriol, represented by the following structural formula, is the aglycone of mangiferin. It is known that the physiological activity of norathyriol is stronger than that of mangiferin. It is also known that norathyriol has physiological activity against colon cancer, lung cancer, breast cancer, diabetes, and nonalcoholic fatty liver disease (NAFLD). On the other hand, norathyriol has a problem that it is present in small amounts in nature. [ka]

[0004] To date, chemical methods and microbial conversion methods using microorganisms have been reported as methods for producing norathyriol from mangiferin.

[0005] As the chemical method, a method based on organic synthesis, decomposition using an acid catalyst, etc. have been proposed. However, the method based on organic synthesis has a problem that it is not economically viable due to the long synthesis steps, and the decomposition using an acid catalyst has a problem that the yield is not high. Also, it is not a very suitable method from an environmental point of view.

[0006] On the other hand, from an environmental point of view, the microbial conversion method is considered to be more suitable than the chemical method. To date, Bacteroides sp. MANG strain (see Non-Patent Document 1) and CG19-1 strain (see Non-Patent Document 2) have been reported as microorganisms capable of catalyzing the conversion of mangiferin to norathyriol. In addition, the CG19-1 strain was identified as Catenibacillus scindens in a later report (see Non-Patent Document 3).

[0007] However, the microorganisms described above are anaerobic, and therefore require special equipment or tools for their cultivation. In addition, the microorganisms described above require the addition of mangiferin as a substrate for the cultivation of the cells having the conversion activity. All of these factors increase the cost of producing norathyriol, which is economically very problematic.

[0008] Therefore, there is currently a strong demand for the prompt provision of a technology that can produce norathyriol from mangiferin, which is found in large quantities in plants, as a method that is simpler, more efficient, safer, and more environmentally friendly than conventional methods. [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] Sanugul K., Akao T., Li Y., Kakiuchi N., Nakamura N., Hattori M., Isolation of a human intestinal bacterium that transforms Mangiferin to Norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond,2005, Biol. Pharm. Bull.,28(9):1672-1678. [Non-Patent Document 2] Braune A., Blaut M., Deglycosylation of puerarin and other aromatic C-glucosides by newly isolated human intestinal bacterium,2011, Environmental Microbiology,13(2):482-494. [Non-Patent Document 3] Braune A., Blaut M., Cantenibacillus scindens gen. nov., sp. nov., a C-deglycosylating human intestinal representative of the Lachnospiraceae,2018,Int. J. Syst. Evol. Microbiol., 68:3356-3361. Summary of the Invention [Problem to be solved by the invention]

[0010] The present invention aims to meet such demands, break through the current situation, solve the above-mentioned conventional problems, and achieve the following objectives: That is, the present invention aims to provide a novel method for producing norathyriol, which can produce norathyriol from mangiferin more simply, efficiently, safely, and environmentally friendly than conventional methods, a microorganism that can be suitably used in the production method, an agent for preparing norathyriol, and a method for producing foods, feeds, cosmetics, medicines, quasi-drugs, etc., containing norathyriol. [Means for solving the problem]

[0011] As a result of intensive research to achieve the above-mentioned objective, the inventors have discovered that by using a microorganism belonging to the genus Bacillus that has the ability to convert mangiferin into norathyriol, it is possible to efficiently produce norathyriol from mangiferin in a manner that is simpler than conventional methods.

[0012] The present invention is based on the unique findings of the present inventors, and the means for solving the above problems are as follows. <1> The method for producing norathyriol using a microorganism is characterized in that the microorganism belongs to the genus Bacillus and is capable of converting mangiferin into norathyriol. <2> The microorganism is prepared by culturing in the absence or presence of mangiferin. <1> This is a method for producing norathyriol described in the above. <3> The microorganism is prepared by culturing under aerobic or anaerobic conditions. <1> or <2> This is a method for producing norathyriol described in the above. <4> The microorganism is prepared by culturing at a temperature of less than 70° C. <1> ~ <3> 13. A method for producing norathyriol according to any one of claims 1 to 12. <5> The method for producing norathyriol is characterized in that at least one selected from the group consisting of resting cells of the microorganism, a cell disruptant of the microorganism, and a cell extract of the microorganism is used. <1> ~ <4> 13. A method for producing norathyriol according to any one of claims 1 to 12. <6> The method of the present invention is characterized in that the microorganism is cultured in the presence of mangiferin to produce norathyriol. <1> ~ <4> 13. A method for producing norathyriol according to any one of claims 1 to 12. <7> The production of norathyriol is carried out under aerobic or anaerobic conditions. <1> ~ <6> 13. A method for producing norathyriol according to any one of claims 1 to 12. <8> The production of norathyriol is carried out under a temperature condition of 70° C. or less. Previous < 1 > ~ < 7 > 13. A method for producing norathyriol according to any one of claims 1 to 12. <9> The microorganism is capable of growing under aerobic or anaerobic conditions at a temperature of less than 70°C. <1> ~ <8> 13. A method for producing norathyriol according to any one of claims 1 to 12. <10> The microorganism is entrustment Number NITE P The Bacillus sp. KM7-1 strain of <1> ~ <9> 13. A method for producing norathyriol according to any one of claims 1 to 12. <11> Receiving entrustment Number NITE P The microorganism is characterized in that it is Bacillus sp. KM7-1 strain of -03226. <12> The present invention relates to an agent for preparing norathyriol, characterized in that it contains at least one selected from the group consisting of a microorganism's cells belonging to the genus Bacillus and having the ability to convert mangiferin into norathyriol, a cell homogenate of the microorganism, and a cell extract of the microorganism. <13> The above <1> from <10> A step of preparing norathyriol by any one of the methods for producing the same; and a step of producing a food, feed, cosmetic, medicine or quasi-drug containing norathyriol using the norathyriol. Effect of the Invention

[0013] According to the present invention, it is possible to solve the above-mentioned problems of the conventional method, and to provide a novel method for producing norathyriol from mangiferin which can produce norathyriol more simply, efficiently, safely and in a more environmentally friendly manner than conventional methods, as well as a microorganism that can be suitably used in the production method, an agent for preparing norathyriol, and a method for producing foods, feeds, cosmetics, pharmaceuticals or quasi-drugs containing norathyriol. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 shows the results of measuring the growth rate of Bacillus sp. KM7-1 strain under various aerobic conditions in Test Example 2. [Diagram 2] FIG. 2 shows the results of measuring the concentration of norathyriol produced by Bacillus sp. KM7-1 strain cultured under various aerobic conditions in Test Example 2. [Diagram 3] FIG. 3 is a graph showing the time course of production of norathyriol from mangiferin in the resting cell reaction of Bacillus sp. KM7-1 strain in Test Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] (Method of producing norathyriol) The method for producing norathyriol of the present invention is a method for producing norathyriol using a microorganism, which includes at least a step of producing norathyriol, and further includes other steps such as a step of preparing an active microorganism and a step of recovering the norathyriol, as necessary.

[0016] <Generation process> The production process is a process of producing norathyriol from mangiferin (hereinafter sometimes referred to as "converting") using a microorganism belonging to the genus Bacillus and having the ability (hereinafter sometimes referred to as "activity") to convert mangiferin into norathyriol.

[0017] -Microorganisms- The microorganism is not particularly limited as long as it belongs to the genus Bacillus and has the ability to convert mangiferin into norathyriol, and can be appropriately selected depending on the purpose.

[0018] The microorganism preferably has the activity of converting mangiferin to norathyriol under at least one of aerobic and anaerobic conditions, and more preferably has the ability to convert mangiferin to norathyriol under aerobic conditions. Furthermore, the microorganism is preferably one that can grow at high temperature under aerobic or anaerobic conditions and can prepare bacterial cells that have the activity of converting mangiferin to norathyriol, and it is more preferable that the microorganism is one that can grow at high temperature under aerobic conditions and can prepare bacterial cells that have the activity of converting mangiferin to norathyriol. The aerobic conditions refer to conditions in which oxygen is present.

[0019] The lower limit of the growth temperature of the microorganism is usually 4° C. or higher, preferably 10° C. or higher, and more preferably 20° C. or higher. The upper limit of the growth temperature of the microorganism is usually less than 70° C., preferably 65° C. or lower, and more preferably 60° C. or lower. The preferred range of the growth temperature of the microorganism is 20 to 65° C., more preferably 30 to 60° C., and even more preferably 40 to 60° C.

[0020] It is preferable that the microorganism has the activity of converting mangiferin to norathyriol even when prepared by culturing in a medium not containing mangiferin.

[0021] The microorganism is a recipient organism having a base sequence of 16S rDNA (16S rRNA gene) represented by SEQ ID NO: 1. entrustment Number NITE P It is preferable that the microorganism has a homology with the partial base sequence of 16S rDNA of Bacillus sp. KM7-1 strain of -03226. The homology is not particularly limited as long as the microorganism has the activity of converting mangiferin to norathyriol, and can be appropriately selected depending on the purpose, but is usually preferably 99.0% or more, more preferably 99.2% or more, and particularly preferably 99.3% or more. The method for analyzing the homology is not particularly limited, and any known method can be appropriately selected, for example, a method performed by BLAST homology search.

[0022] The microorganism may be a entrustment Number NITE P The Bacillus sp. KM7-1 strain is preferably Bacillus sp. KM7-1 strain of the same type as that of the ... entrustment Number NITE P -03226, received date: May 26, 2020).

[0023] It is preferable that the microorganism is essentially a microorganism that has the activity to produce norathyriol from mangiferin, which is a C-glycoside, but does not have the activity to produce the aglycone from puerarin, which is also a C-glycoside.

[0024] The method for obtaining the microorganism is not particularly limited and can be appropriately selected depending on the purpose. For example, the microorganism can be isolated from the intestinal flora of a mouse, fermented foods, plants (flowers, stems, leaves, roots), soil, etc. The method for isolating the microorganism from the intestinal flora of the mouse is not particularly limited, and any general isolation method for intestinal bacteria can be appropriately selected. For example, the microorganism can be obtained by culturing mouse feces under anaerobic conditions using GAM liquid medium and confirming whether the obtained bacterial cells have the activity to convert mangiferin into norathyriol. The culture conditions for the isolation are not particularly limited and can be appropriately selected depending on the purpose. For example, culture can be performed at about 37° C. for about 4 days. There is no particular limitation on the method for confirming whether the obtained bacterial cells have the activity to convert mangiferin into norathyriol, and it can be selected appropriately depending on the purpose.For example, it can be performed in the same manner as the [Activity Measurement] described in the [Examples] section below.

[0025] The method for preparing the microorganisms (hereinafter sometimes referred to as "active microorganisms") used in the production process from the obtained microorganisms is not particularly limited and can be appropriately selected depending on the purpose. For example, the microorganisms may be prepared by culturing in the absence of mangiferin, or may be prepared by culturing in the presence of mangiferin. Furthermore, the microorganisms may be prepared by culturing under aerobic conditions, or may be prepared by culturing under anaerobic conditions. In this case, those prepared by culturing under temperature conditions of less than 70°C can be used as appropriate.

[0026] -Mangiferin- The mangiferin may be a commercially available product, or may be prepared from a plant by a known method. The mangiferin may be purified, or may be unpurified or crudely purified, which contains components other than mangiferin and is prepared from a plant.

[0027] -Generate- The method of producing the above-mentioned is not particularly limited as long as it can produce norathyriol from mangiferin, and can be appropriately selected according to purpose, and for example, can be the mode of using the cell of the above-mentioned microorganism in a growing state, the mode of using the cell of the above-mentioned microorganism in a resting state, the mode of using the cell crushed material or cell extract of the above-mentioned microorganism, etc. These can be used alone or in combination of two or more kinds. In the present invention, the microorganism in "producing norathyriol using a microorganism" includes the form of a bacterial cell, and the form of a treated bacterial cell such as a bacterial cell disruptant or a bacterial cell extract. The microorganisms or treated bacterial cells may be used after being immobilized on a carrier.

[0028] The preparation method of the cell disruption or cell extract is not particularly limited, and can be selected as appropriate, as long as it can produce norathyriol from mangiferin using the cell disruption or cell extract.Whether or not it can produce norathyriol from mangiferin using the cell disruption or cell extract prepared can be performed, for example, in the same manner as [activity measurement] described in the section [Example] below.

[0029] The production step can be carried out using the cells in a growing state as described above, but is particularly preferably carried out by a resting cell reaction using cells in a resting state. The resting cell reaction refers to a reaction for producing norathyriol from mangiferin in a state where the growth and proliferation of microorganisms are stopped.

[0030] --Aspects of using microbial cells in a growing state-- The mode of using the microbial cells in the proliferating state is not particularly limited and can be appropriately selected depending on the purpose. For example, the mode of using the microbial cells in the proliferating state can be selected by culturing the microbial cells in the presence of mangiferin.

[0031] In the embodiment in which the cells of the microbial organism in a proliferating state are used, the medium is not particularly limited and may be appropriately selected from media used for culturing known microorganisms, such as bouillon medium (NB medium).

[0032] The contents of the bacterial cells and the mangiferin in the medium are not particularly limited, and can be appropriately selected in consideration of, for example, the amount of the bacterial cells of the growing microorganism and the production efficiency of norathyriol.

[0033] --Modes using dormant microbial cells, modes using microbial cell lysates or cell extracts-- The mode of using the dormant microorganism cells, the mode of using the crushed microorganism cells or the extract of the microorganism cells is not particularly limited and can be appropriately selected according to the purpose, and for example, the method of reacting at least one of the dormant microorganism cells, the crushed microorganism cells, and the extract of the microorganism cells with the mangiferin in a liquid containing other components as necessary, etc. The method may be carried out using only the dormant microorganism cells, the crushed microorganism cells, and the extract of the microorganism cells, and the mangiferin.

[0034] The liquid is not particularly limited and can be appropriately selected depending on the purpose, and examples thereof include sodium phosphate buffer (phosphate buffer), sodium acetate buffer (acetate buffer), citric acid-potassium citrate buffer (citric acid buffer), citrate phosphate buffer, borate buffer, tartrate buffer, phthalate buffer, Tris buffer, McIlvaine buffer, ammonium chloride buffer, HEPES buffer, sodium lactate buffer (lactate buffer), Tris hydrochloric acid buffer, tap water, purified water, physiological saline, etc. These may be used alone or in combination of two or more. The suitable pH of the liquid is usually in the range of pH 4 to 10, preferably pH 5 to 9, more preferably pH 6 to 8.

[0035] The total content of the dormant microbial cells, crushed microbial cells, and extract of the microbial cells in the liquid, as well as the content of mangiferin, are not particularly limited, and can be selected appropriately taking into consideration, for example, the total content of the dormant microbial cells, crushed microbial cells, and extract of the microbial cells, as well as the efficiency of norathyriol production. For example, the content of the mangiferin in the liquid is usually in the concentration range of 0.01 to 100 mM, preferably 0.1 to 10 mM.

[0036] The other components are not particularly limited and can be appropriately selected depending on the purpose. For example, a solvent for dissolving the mangiferin can be mentioned. The solvent for dissolving the mangiferin is not particularly limited and can be appropriately selected depending on the purpose, and examples thereof include aprotic polar solvents such as dimethylsulfoxide (hereinafter sometimes referred to as "DMSO"), dimethylformamide (hereinafter sometimes referred to as "DMF"), tetrahydrofuran (hereinafter sometimes referred to as "THF"), acetonitrile, and acetone, and protic polar solvents such as ethanol, methanol, isopropanol, n-butanol, and acetic acid. These may be used alone or in combination of two or more. The content of other components in the liquid is not particularly limited and can be appropriately selected depending on the purpose.

[0037] The conditions for the production step are not particularly limited and can be appropriately selected depending on the purpose. The conditions may be aerobic or anaerobic, but are preferably aerobic.

[0038] The lower limit of the temperature in the production step (hereinafter sometimes referred to as "reaction temperature") is not particularly limited and can be appropriately selected depending on the purpose, but is usually 10°C or higher, preferably 20°C or higher, and more preferably 30°C or higher. The upper limit of the temperature in the production step is usually 70°C or lower, and more preferably 60°C or lower. The suitable temperature range for the production step is preferably 20 to 70°C, and more preferably 30 to 60°C. The reaction temperature may be constant or may be changed during the production process. For example, when the production process is carried out using the cells of a growing microorganism, the reaction temperature may be treated at a certain temperature suitable for the growth of the microorganism or a certain temperature suitable for the production of norathyriol, or the reaction temperature may be appropriately changed to a temperature suitable for the production of norathyriol after treatment for a certain period of time at a temperature suitable for the growth of the microorganism.

[0039] The time for the formation step is not particularly limited and can be appropriately selected depending on the purpose. For example, the time is usually 1 hour or more, and preferably 5 to 50 hours.

[0040] <Other processes> The other steps are not particularly limited as long as they do not impair the effects of the present invention, and can be appropriately selected depending on the purpose. For example, an active microorganism preparation step, a recovery step, and the like can be mentioned.

[0041] -Active microorganism preparation process- The microorganism preparation step is a step of preparing the microorganisms to be used in the production step described above.

[0042] The method for preparing the microorganism is not particularly limited and can be appropriately selected depending on the purpose, and examples thereof include a step of culturing and growing the microorganism in a medium, etc. The obtained bacterial cells may be subjected to treatment such as washing, concentration, drying, crushing, pulverization, extraction, immobilization, etc., as necessary, before being subjected to the production step.

[0043] The medium is not particularly limited, and a medium used for culturing known microorganisms can be appropriately selected, for example, bouillon medium (NB medium) and the like. The suitable pH of the medium is usually in the range of pH 4 to 10, preferably pH 5 to 9, more preferably pH 6 to 8. The medium may or may not contain mangiferin, but it is preferable that the medium does not contain mangiferin. As shown in the section of [Examples] below, in the present invention, even if a microorganism prepared by culturing in a medium not containing mangiferin is used, mangiferin can be converted to norathyriol in the production step. Therefore, a microorganism having a desired activity can be prepared even without containing mangiferin in the medium, and the present invention is also very advantageous in terms of cost.

[0044] The culture method is not particularly limited, and any known culture method for microorganisms can be appropriately selected.

[0045] The conditions for the culture are not particularly limited and can be appropriately selected depending on the purpose. The culture may be performed under aerobic conditions or anaerobic conditions, with aerobic conditions being preferred.

[0046] The culture temperature is not particularly limited and can be appropriately selected depending on the purpose, for example, depending on the growth temperature of the above-mentioned microorganism.

[0047] The culture period is not particularly limited and can be appropriately selected depending on the purpose. For example, the culture period is usually 1 hour or more, and preferably 1 to 5 days.

[0048] The container used for the culture is not particularly limited and can be appropriately selected depending on the purpose.

[0049] The culture method is not particularly limited and can be appropriately selected depending on the purpose. Examples of the culture method include static culture, aeration culture, stirring culture, shaking culture, batch culture, semi-batch culture (fed-batch culture), and continuous culture.

[0050] -Recovery process- The recovery step is a step of recovering norathyriol produced in the production step.

[0051] The method for recovering the norathyriol is not particularly limited, and a known method can be appropriately selected according to the purpose, for example, a solvent extraction method, a method utilizing the difference in adsorption affinity for various adsorbents, a chromatography method, etc. These may be used alone or in combination of two or more.

[0052] The norathyriol recovered in the recovery step may be purified, may be crudely purified, or may be unpurified.

[0053] The uses of norathyriol produced by the norathyriol production method of the present invention are not particularly limited and can be appropriately selected depending on the purpose. For example, it can be suitably used in foods, feeds, cosmetics, pharmaceuticals, quasi-drugs, etc.

[0054] (microorganisms) One embodiment of the microorganism of the present invention is the above-mentioned receptor. entrustment Number NITE P The strain is Bacillus sp. KM7-1, which is designated as -03226.

[0055] (Noratiryol preparation agent) The agent for preparing norathyriol of the present invention contains at least one selected from the group consisting of a microorganism belonging to the genus Bacillus and having the ability to convert mangiferin into norathyriol, a disrupted body of the microorganism, and a body extract of the microorganism, and may further contain other components as necessary.

[0056] <At least one selected from the group consisting of a microorganism belonging to the genus Bacillus and having the ability to convert mangiferin into norathyriol, a disrupted body of the microorganism, and a body extract of the microorganism> The cells of the microorganism belonging to the genus Bacillus and having the ability to convert mangiferin into norathyriol, the disrupted cells of the microorganism, and the cell extract of the microorganism are the same as those described in the <Production process> section of the (Norathyriol production method) of the present invention above, and the preferred embodiments are also the same. The microbial cells, disrupted cells, and extracts of cells may be used alone or in combination of two or more kinds.

[0057] <Other configurations> The other configurations are not particularly limited as long as they do not impair the effects of the present invention and can be selected appropriately depending on the purpose. Examples of the other configurations include liquids such as buffer solutions and water, and solvents for dissolving the mangiferin in the liquid.

[0058] (Production methods for food, feed, cosmetics, medicines and quasi-drugs) The method for producing foods, feeds, cosmetics, pharmaceuticals, quasi-drugs, etc. of the present invention includes at least a norathyriol preparation step and a production step, and may further include other steps as necessary.

[0059] <Noratiriol Preparation Step> The norathyriol preparation step is a step of preparing norathyriol by the above-mentioned method for producing norathyriol of the present invention, and can be carried out in the same manner as described in the above section (Method for producing norathyriol).

[0060] <Manufacturing process> The production step is a step of producing foods, feeds, cosmetics, medicines, quasi-drugs, etc. containing norathyriol by using the norathyriol obtained in the norathyriol preparation step. The method for the production step is not particularly limited as long as the norathyriol obtained in the preparation step is used, and a known production method for food, feed, cosmetics, medicines or quasi-drugs can be appropriately selected, for example, a method of blending the norathyriol into the raw materials of food, feed, cosmetics, medicines or quasi-drugs, etc., or adding the norathyriol to the produced food, feed, cosmetics, medicines or quasi-drugs, etc. In addition, when the norathyriol obtained in the norathyriol preparation step is used as it is or purified to produce a food, feed, cosmetics, medicines or quasi-drugs containing norathyriol, the step of blending or adding norathyriol to the raw materials can be omitted.

[0061] The type of the food, feed, cosmetic, medicine or quasi-drug is not particularly limited and can be appropriately selected depending on the purpose. The food products also include beverages, functional foods, health foods, and the like. Examples of the cosmetics include skin cosmetics, makeup cosmetics, cleansing agents, hair cosmetics, hair cleansing agents, hair restorers, hair dyes, bleaches, and waving liquids.

[0062] <Other processes> The other steps are not particularly limited as long as they do not impair the effects of the present invention, and can be appropriately selected depending on the purpose. EXAMPLES

[0063] The present invention will be described below with reference to test examples, but the present invention is not limited to these test examples.

[0064] (Test Example 1: Isolation and identification of strains) <Isolation of strains> A strain having the ability to convert mangiferin to norathyriol from mouse feces was isolated as follows. (1) Mouse feces was cultured in GAM liquid medium (manufactured by Nissui Pharmaceutical Co., Ltd.) under anaerobic conditions (using the anaerobic culture kit "Anelopac" manufactured by Mitsubishi Gas Chemical Co., Ltd.) at 37°C for 4 days. Using a portion of the obtained bacterial cells, it was confirmed whether or not they had the activity to convert mangiferin to norathyriol by the following [activity measurement]. [Activity measurement] The obtained bacterial cells (amount of bacterial cells obtained in 10 mL of culture medium) were used to carry out a resting cell reaction at 37°C for 24 hours under aerobic conditions in 50 mM sodium phosphate buffer (pH 7.3) containing 1 mM mangiferin and 5% DMSO (all concentrations indicate final concentrations; total reaction volume was 0.1 mL). After the reaction was completed, the reaction solution was extracted with 1-butanol, and the 1-butanol layer was subjected to the following liquid chromatography analysis to quantitatively determine the amounts of mangiferin as a substrate and norathyriol as a purified product. - Liquid chromatography analysis - Separation was performed using the equipment and conditions shown below, and mangiferin and norathyriol were quantified by comparison with standard specimens. Equipment: Acquity H-Class UPLC system Column: Waters HSS T3 φ 2.1×50(mm) Detection wavelength: 310nm Elution solvent: 30-75% methanol (concentration gradient) + 0.1% trifluoroacetic acid · Flow rate: 0.6mL / min

[0065] (2) The remaining bacterial cells obtained in (1) above were serially diluted with physiological saline (10, 10 2 , 10 3 , 10 4 , 10 5 2x dilution).

[0066] (3) 100 μL of the dilution prepared in (2) above was spread onto GAM agar medium (1.5% agar added to GAM liquid medium manufactured by Nissui Pharmaceutical Co., Ltd.) in a 9 cm diameter Petri dish (2 plates per dilution) and cultured at 37°C for 4 days under anaerobic conditions.

[0067] (4) Separate colonies appeared. 5 All the bacteria on one of the Petri dishes coated with the 2-fold diluted solution were collected, and the activity of converting mangiferin to norathyriol was confirmed in the same manner as in the [activity measurement] described in (1) above. Then, 13 colonies were picked from the other Petri dish, inoculated onto GAM agar medium (two plates each) in another Petri dish, and cultured under the same conditions as in (3) above.

[0068] (5) The 13 strains were recovered from one Petri dish and activity measurements were performed in the same manner as described in (1) above. Three strains were found to have the activity to convert mangiferin to norathyriol.

[0069] (6) For the three strains in which the above activity was observed, strains were recovered from another Petri dish and colonies were again created in the same manner as described above in (2), (3), and (4). Activity measurements were performed in the same manner as described in (1) above to confirm that these colonies had the activity to convert mangiferin to norathyriol.

[0070] As a result, a strain having the ability to convert mangiferin to norathyriol was isolated.

[0071] <Identification of strains> Analysis of the 16S rDNA sequences of the three strains isolated above revealed that they had exactly the same sequences. Therefore, we selected the most typical strain, KM7-1, and performed molecular phylogenetic analysis (based on the results of partial 16S rDNA sequence analysis) to identify the strain. The analysis was performed using ENKI (Techno Suruga Lab., Inc.) as analysis software and a BLAST homology search using DB-BA14.1 (Techno Suruga Lab., Inc.) and the international nucleotide sequence database (DDBJ / ENA (EMBL) / GenBank) as the database. As a result, the strain that showed the highest homology was Bacillus hisashii N-11 strain (Accession No. AB618491) (homology rate 495 / 499, 99.2%), and the KM7-1 strain was considered to belong to the genus Bacillus. Therefore, the KM7-1 strain was designated as Bacillus sp. KM7-1 strain. The partial base sequence (499 bp) of 16S rDNA of the KM7-1 strain was as shown in SEQ ID NO:1.

[0072] The Bacillus sp. KM7-1 strain was deposited at the National Institute of Technology and Evaluation, Biotechnology Center, Patent Microorganism Depositary (NPMD) (2-5-8 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan). entrustment Number NITE P -03226, received date: May 26, 2020).

[0073] (Test Example 2: Growth and conversion activity under aerobic conditions) <Growth> Bacillus sp. KM7-1 strain was cultured under the following culture conditions. [Growth temperature] 37℃, 45℃, or 50℃ [Culture vessel and medium volume] 30 mL of bouillon medium (NB medium) in a 50 mL Erlenmeyer flask, 10 mL of bouillon medium (NB medium) in a 20 mL Erlenmeyer flask, or 10 mL of bouillon medium (NB medium) in a 25 mm diameter test tube [Culture period] 1, 2, 3, 4 or 5 days [Type of culture] Static or shaking culture

[0074] Figure 1 shows the growth rate (cell mass (mg) per 10 mL of medium) of Bacillus sp. KM7-1 strain cultured under the above culture conditions. In Figure 1, black bars show the results for stationary culture, and white bars show the results for shaking culture.

[0075] <Activity measurement> The resting cell reaction was carried out in the same manner as in [Activity Measurement] of Test Example 1 above, except that the cells obtained by culturing under the above culture conditions were used and the amount of norathyriol produced was measured. Wet cell mass: 12mg, 18mg, 20mg, 25mg, or 35mg

[0076] The results of measuring the norathyriol production concentration (μM) obtained in the resting cell reaction using the cells cultured under the above culture conditions are shown in Figure 2. In Figure 2, the black bars show the results when statically cultured cells were used, and the white bars show the results when shaking cultured cells were used.

[0077] From the above results, it was confirmed that Bacillus sp. KM7-1 grows well aerobically, efficiently converts mangiferin to norathyriol in the aerobic resting cell reaction, and shows better growth at 50°C than at 37°C. In addition, since the Bacillus sp. KM7-1 strain had almost the same conversion activity at the same cell mass regardless of the number of days of culture, and since mangiferin was not added to the medium during growth, it is inferred that the conversion enzyme that converts mangiferin to norathyriol is constitutively expressed. It was also confirmed that, regardless of the type of culture vessel, Bacillus sp. KM7-1 strain grew better in static culture than in shake culture, grew better in Erlenmeyer flask culture than in test tube culture, and showed maximum growth on the second day of growth.

[0078] (Test Example 3: Time course of norathyriol production from mangiferin by resting cell reaction) Bacillus sp. KM7-1 strain was cultured in 10 mL of bouillon medium (NB medium) in a 20 mL Erlenmeyer flask at 50°C for 3 days under static conditions, and the resulting cells (8 mg or 16 mg) were used to perform a time course experiment on the conversion of mangiferin to norathyriol. <Activity measurement> An experiment on the time course of the conversion of mangiferin to norathyriol was performed using a resting cell reaction in the same manner as in [Activity Measurement] of Test Example 1 above, except that the above-mentioned amounts of cells obtained by culturing under the above-mentioned culture conditions were used and the reaction time was 36 hours, and the concentrations of remaining mangiferin and norathyriol produced were measured.

[0079] Figure 3 shows the results of measuring the norathyriol production concentration (μM) over time obtained in the resting cell reaction using the cells cultured under the above culture conditions, and the results of measuring the remaining mangiferin concentration (μM) over time. In Figure 3, "○" indicates the norathyriol production concentration when 8 mg of cells are used ("8 mg (Nora)"), "□" indicates the norathyriol production concentration when 16 mg of cells are used ("16 mg (Nora)"), "●" indicates the remaining mangiferin concentration when 8 mg of cells are used ("8 mg (Mang)"), and "■" indicates the remaining mangiferin concentration when 16 mg of cells are used ("16 mg (Mang)").

[0080] As shown in FIG. 3, norathyriol was produced with a high conversion rate, and the initial production rate corresponded to the amount of bacterial cells.

[0081] As described above, unlike the microorganisms reported so far that have the activity of converting mangiferin to norathyriol, the microorganism of the present invention can be cultured under aerobic conditions, does not require the addition of a substrate (mangiferin) to induce the conversion enzyme, and the conversion reaction from mangiferin to norathyriol can proceed under aerobic conditions. In addition, since the microorganism of the present invention has the activity of converting mangiferin to norathyriol in a resting cell reaction, the reaction can be carried out in a buffer solution containing only the substrate mangiferin, and the reaction can also be carried out in a system that does not contain any other components other than the substrate. Therefore, according to the present invention, a conversion system that is economically excellent, safe, and environmentally friendly can be constructed without requiring special culture conditions or special equipment and instruments. Furthermore, since mangiferin is present in large quantities in plants and can be supplied at low cost, the present invention makes it possible to produce norathyriol, which has previously been expensive, at low cost and stably, and supply it to the market. [Accession number]

[0082] NITE P -03226

Claims

1. A method for producing norathyriol using a microorganism, characterized in that the microorganism is Bacillus sp. KM7-1 strain having accession number NITE P-03226.

2. The method for producing norathyriol according to claim 1, characterized in that the microorganism is prepared by culturing in the absence or presence of mangiferin.

3. The method for producing norathyriol according to claim 1 or 2, characterized in that the microorganism is prepared by culturing under aerobic or anaerobic conditions.

4. The method for producing norathyriol according to any one of claims 1 to 3, characterized in that the microorganism is prepared by culturing it under a temperature condition of less than 70°C.

5. The method for producing norathyriol according to any one of claims 1 to 4, characterized in that norathyriol is produced using at least one selected from the group consisting of resting cells of the microorganism, cell disruption products of the microorganism, and cell extracts of the microorganism.

6. The method for producing norathyriol according to any one of claims 1 to 4, characterized in that norathyriol is produced while culturing the microorganism in the presence of mangiferin.

7. The method for producing norathyriol according to any one of claims 1 to 6, characterized in that the production of norathyriol is carried out under aerobic or anaerobic conditions.

8. The method for producing norathyriol according to any one of claims 1 to 7, characterized in that the production of norathyriol is carried out under a temperature condition of 70°C or less.

9. The method for producing norathyriol according to any one of claims 1 to 8, wherein the microorganism is capable of growing under aerobic or anaerobic conditions at a temperature of less than 70°C.

10. A microorganism which is Bacillus sp. KM7-1 strain having accession number NITE P-03226.

11. An agent for preparing norathyriol, comprising at least one selected from the group consisting of a microbial cell of Bacillus sp. KM7-1 strain having accession number NITE P-03226, a disrupted microbial cell of said microorganism, and a microbial cell extract of said microorganism.

12. A process for preparing norathyriol by the process according to any one of claims 1 to 9; A method for producing food, feed, cosmetics, medicines or quasi-drugs, comprising the step of producing food, feed, cosmetics, medicines or quasi-drugs containing norathyriol using the norathyriol.

Citation Information

Patent Citations

  • Antithrombotic containing xanthone derivative or its ester as effective component

    JP1992368379A